Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib HCD122 plus bendamustine in rituximab-refractory CD40-positive follicular lymphoma
NL-OMON36558Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lucatumumab and bendamustine in follicular lymphoma (FL), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities and Safety and tolerability. Planned start Feb 2011; status: withdrawn.
02
Drugs
lucatumumabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON36558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36558.